

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
1481/65019-CA-Z-PCT-
US/JPW/AJM/CYSerial No.
Not Yet KnownINFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)Applicants
Marc Feldmann, et al.Filing Date
January 20, 2004Group
Not Yet Known

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	US 5 6 7 2 3 4 7	9/30/1997	Aggarwal et al.			
	US 5 3 1 7 0 1 9	5/31/1994	Bender et al.			
	US 4 6 9 5 4 5 9	9/22/1987	Steinman et al.			
	US 5 5 0 2 0 6 6	3/26/1996	Heinemann et al.			

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
	WO 8 9 0 8 4 6 0	9/21/1989	PCT				
	WO 9 2 0 8 4 7 4	5/29/1992	PCT				
	WO 9 2 0 7 5 8 5	5/14/1992	PCT				
	WO 9 8 2 4 4 6 3	6/11/1998	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Horneff, G., et al., "Elevated levels of circulating tumor necrosis factor- α , interferon- γ , and interleukin-2 in systemic reactions induced by anti-CD4 therapy in patients with rheumatoid arthritis", <u>Cytokine</u> , 3(3):266-247 (1991);
	Brennan, F., et al. "Inhibitory effect of TNF α antibodies on synovial cell interleukin-1 production in rheumatoid arthritis", <u>The Lancet</u> , 2(8657):244-247 (1989);
	Steinbruchel, D., et al., "Monoclonal antibody treatment (anti-CD4 and anti-interleukin-2 receptor) combined with cyclosporine A has a positive but not simple dose-dependent effect on rat renal allograft survival", <u>Scandinavian J. Immunol.</u> , 34(5):627-633 (1991);
	Breedveld, F., et al., "Anti-CD4 antibodies in rheumatoid arthritis", <u>Clin. Experimental Rheum.</u> , 10(4):325-326 (1992);
	Brennan, F., et al., TNF α – a pivotal role in rheumatoid arthritis?", <u>British J. Rheumatology</u> , 31(5):293-298 (1992);
	Elliott, M.J., et al., "Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to TNF- α : safety, clinical efficacy and control of the acute phase response", <u>Cell. Biochemistry. Supplement</u> , 0(17B):145 (1993); Abstract EZ405;

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this from with next communication to applicant.

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 1481/65019-CA-Z-PCT- US/JPW/AJM/CY		Serial No. Not Yet Known								
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				Applicants Marc Feldmann, et al.		Group Not Yet Known								
				Filing Date January 20, 2004										
U.S. PATENT DOCUMENTS														
Examiner Initial		Document Number							Date	Name	Class	Subclass	Filing Date if Appropriate	
	US	5	5	8	0	8	7	3	12/3/1996	Bianco et al.				
	US	5	6	5	6	2	7	2	8/12/1997	Le et al.				
	US	5	2	0	4	3	2	9	4/20/1993	Ackerman et al.				
	US	5	6	9	8	1	9	5	12/16/1997	Le et al.				
FOREIGN PATENT DOCUMENTS														
		Document Number							Date	Country	Class	Subclass	Translation	
													Yes	No
	WO	9	2	0	7	0	7	6	4/30/1992	PCT				
	WO	9	1	1	0	7	2	2	7/25/1991	PCT				
	WO	9	0	1	5	1	5	2	12/13/1990	PCT				
	WO	9	2	1	6	5	5	3	10/24/1996	PCT				
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)														
	Williams, R.O., et al., "Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis", <u>Proc. Natl. Acad. Sci. USA</u> , 91:2762-2766 (1994);													
	Ralph, P., "Clinical and Preclinical Studies Presented at the Keystone Symposium on Arthritis, Related Diseases, and Cytokines", <u>Lymphokine Cytokine Research</u> , 12(4):261-263 (1993);													
	Racadot, E., "Immunological follow-up of 17 patients with rheumatoid arthritis treated <i>in vivo</i> with an anti-T CD4+ monoclonal antibody (B-F5)", <u>Clinical Experimental Rheumatology</u> , 10:365-374 (1992);													
	Williams, R.O., et al., "Successful therapy of collagen-induced arthritis with TNF receptor-IgG fusion protein and combination with anti-CD4", <u>Immunology</u> , 84:433-439 (March 1995);													
	Van Der Lubbe, P.A., et al., "A Randomized, Double-Blind, Placebo-Controlled Study of CD4 Monoclonal Antibody Therapy In Early Rheumatoid Arthritis", <u>Arth. Rheuma.</u> , 38(8):1097-1106 (1995);													
	Choy, E.H.S., et al., "Therapeutic Monoclonal Antibodies", <u>British J. Rheumatology</u> , 34:707-715 (1995);													
EXAMINER									DATE CONSIDERED					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this from with next communication to applicant.														

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 1481/65019-CA-Z-PCT- US/JPW/AJM/CY		Serial No. Not Yet Known	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				Applicants Marc Feldmann, et al.			
				Filing Date January 20, 2004		Group Not Yet Known	

U.S. PATENT DOCUMENTS													
Examiner Initial		Document Number							Date	Name	Class	Subclass	Filing Date if Appropriate
	US	5	9	1	9	4	5	2	7/6/1999	Le et al.			
	US	5	7	9	5	9	6	7	8/18/1998	Aggarwal et al.			
	US	5	9	9	4	5	1	0	11/30/1999	Adair et al.			
	US	5	0	9	6	9	0	6	3/17/1992	Mandell et al.			

FOREIGN PATENT DOCUMENTS															
		Document Number							Date	Country	Class	Subclass	Translation		
														Yes	No
	WO	9	5	0	9	6	5	2	4/13/1995	PCT					
	WO	9	6	3	3	2	0	4	10/24/1996	PCT					
	WO	0	0	5	0	0	7	9	8/31/2000	PCT					
	EP	0	2	4	0	3	4	4	10/7/1987	EPO					

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Rankin, E.C.C., et al., "The Therapeutic Effects of an Engineered Human Anti-Tumor Necrosis Factor Alpha Antibody (CDP571) in Rheumatoid Arthritis", <u>British J. Rheumatology</u> , 34:334-342 (1995);
	Butler, D.M., et al., "Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF- α antibody with the interleukin-1 receptor antagonist", <u>Eur. Cytokine Netw.</u> , 6(4):225-230 (1995);
	Horneff, G., et al., "Treatment of Rheumatoid Arthritis with an Anti-CD4 Monoclonal Antibody", <u>Arth. Rheumatism</u> , 34(2):129-140 (1991);
	Van Dullemen, H.M., et al., "Treatment of Crohn's Disease With Anti-Tumor Necrosis Factor Chimeric Monoclonal Antibody (cA2)", <u>Gastroenterology</u> , 109(1):129-135 (1995);
	Watts, R.A., and Issacs, J.D., "Immunotherapy of rheumatoid arthritis", <u>Annals Rheumatic Diseases</u> , 51:577-579 (1992);
	Schacht, E., "Gegernwärtige und zukünftige Therapiestrategien der rheumatoiden Arthritis (RA) ["The current and future therapy strategies of rheumatoid arthritis (RA)"]", <u>Zeitschrift für Rheumatologie</u> , 52(6):365-382 (1993);

EXAMINER	DATE CONSIDERED
-----------------	------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this from with next communication to applicant.

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 1481/65019-CA-Z-PCT- US/JPW/AJM/CY		Serial No. Not Yet Known									
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				Applicants Marc Feldmann, et al.		Group Not Yet Known									
				Filing Date January 20, 2004											
U.S. PATENT DOCUMENTS															
Examiner Initial		Document Number							Date	Name	Class	Subclass	Filing Date if Appropriate		
	US	5	6	5	8	5	7	0	8/19/1997	Newman et al.					
	US	6	0	1	5	5	5	7	1/18/2002	Tobinick et al.					
	US	6	1	7	7	0	7	7	1/23/2001	Tobinick et al.					
	US	5	9	5	8	4	1	3	9/28/1999	Anagnostopoulos et al.					
FOREIGN PATENT DOCUMENTS															
		Document Number							Date	Country	Class	Subclass	Translation		
													Yes	No	
	AS	5	8	9	7	6	9	0	9/22/1987	Australia					
	CA	2	0	2	1	3	6	9	1/19/1991	Canada					
	DE	4	0	0	6	2	6	9	2/28/1990	Germany					
	GB	2	2	4	6	5	6	9	6/15/1990	Great Britain					
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)															
	Elliott, M.J., et al., "Treatment of Rheumatoid Arthritis with Chimeric Monoclonal Antibodies to TNF α ", <u>Rev. Esp. Reumatol.</u> , 20 (Suppl. 1):148 (1993); Abstract 320;														
	Natanson, C., et al., "Selected Treatment Strategies for Septic Shock Based on Proposed Mechanism of Pathogenesis", <u>Annals Internal Med.</u> , 120(9):771-783 (1994);														
	Hervé, P., et al., "Phase I-II Trial of a Monoclonal Anti-Tumor Necrosis α Factor Antibody for the Treatment of Refractory Severe Acute Graft-Versus-Host Disease", <u>Blood</u> , 79(12):3362-3368 (1992);														
	Thorbecke, G.J., et al., "Involvement of endogenous tumor necrosis factor α and transforming growth factor β during induction of collagen type II arthritis in mice", <u>Proc. Natl. Acad. Sci. USA</u> , 89:7375-7379 (1992);														
	Piguet, P.F., et al., "Evolution of collagen arthritis in mice is arrested by treatment with anti-tumor necrosis factor (TNF) antibody or a recombinant soluble TNF receptor", <u>Immunology</u> , 77:510-514 (1992);														
	Brahn, E., et al., "Effects of Tumor Necrosis Factor and Combination Cyclosporin A/Methotrexate Therapy on Collagen Arthritis", <u>Arthritis Rheum.</u> , 32(4 Suppl.) S133 (1989); Abstract D42;														
EXAMINER								DATE CONSIDERED							
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this from with next communication to applicant.															

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 1481/65019-CA-Z-PCT- US/JPW/AJM/CY		Serial No. Not Yet Known							
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				Applicants Marc Feldmann, et al.		Group Not Yet Known							
				Filing Date January 20, 2004									
U.S. PATENT DOCUMENTS													
Examiner Initial		Document Number						Date	Name	Class	Subclass	Filing Date if Appropriate	
	US	6	1	9	0	6	9	1	2/20/2001	Mak			
	US	5	2	9	8	3	9	6	3/29/1994	Kotzin et al.			
	US	5	4	6	8	4	8	1	11/21/1995	Sharma et al.			
	US	5	2	6	0	4	2	2	11/9/1993	Clark et al.			
FOREIGN PATENT DOCUMENTS													
		Document Number						Date	Country	Class	Subclass	Translation	
												Yes No	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)													
	Markowitz, J., et al., "Immunology of Inflammatory Bowel Disease: Summary of the Proceedings of the Subcommittee on Immunosuppressive Use in IBD", <u>J. Ped. Gastroenterology Nutrition</u> , 12:411-423 (1991);												
	Cohen, S., et al., "Comparison of the Safety and Efficacy of Cyclosporine-A and Methotrexate in Refractory Rheumatoid Arthritis: A Randomized, Multi-Centered, Placebo-Controlled Trial", <u>Rev. Esp. Reumatol.</u> , 20 (Suppl. 1):148 (1993); Abstract 318;												
	Pascalis, L., et al., "Longterm Efficacy and Toxicity of Combined Cyclosporine A-Steroid-Methotrexate Treatment in Rheumatoid Arthritis", <u>Rev. Esp. Reumatol.</u> , 20 (Suppl. 1):148 (1993); Abstract 319;												
	Arend, W.P., et al. (1990) <u>Arthritis Rheum.</u> , 33(3):305-315;												
	Bach, J.F. (1993) <u>TiPs</u> , 14:213-216;												
	Barrera, P., et al. (1995) <u>Br. J. Rheumatol.</u> , 34:747-755;												
	Barrera, P. (1995) <u>Cytokine</u> , 3(5):504 (Abstract 330);												
EXAMINER								DATE CONSIDERED					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this from with next communication to applicant.													

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
1481/65019-CA-Z-PCT-
US/JPW/AJM/CYSerial No.
Not Yet KnownINFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)Applicants
Marc Feldmann, et al.Filing Date
January 20, 2004Group
Not Yet Known

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Bologna, C., et al. (1996) <u>Presse Med.</u> , 25:876-878, XP002048553;
	Borigini, M.J., et al. (1995) <u>Baillière's Clin. Rheum.</u> , 9(4):689-710;
	Brennan, et al. (1994) <u>Clin. Exp. Immunol.</u> , 97:1-3;
	Cooper, K.D. (1993) <u>Clin. Rev. Allergy</u> , 11:543-559;
	Debets, et al. (1994) <u>Immunology Today</u> , 15:455-458;
	Elliott, M.J., et al. (1993) <u>Arth. Rheum.</u> , 36(12):1681-1690;
	Elliott, M.J., et al. (1994) <u>Int. Arch. Allergy Immunol.</u> , 104:112-125;
	Elliott, M.J., et al. (1994) <u>Lancet</u> , 344:1105-1110;
	Elliott, M.J., et al. (1994) <u>Lancet</u> , 344:1125-1127;

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 1481/65019-CA-Z-PCT- US/JPW/AJM/CY		Serial No. Not Yet Known	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				Applicants Marc Feldmann, et al.		Group Not Yet Known	
				Filing Date January 20, 2004			
U.S. PATENT DOCUMENTS							
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
FOREIGN PATENT DOCUMENTS							
		Document Number	Date	Country	Class	Subclass	Translation
							Yes No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
		Feldmann, M., et al. (1996) <u>Ann. Rev. Immunol.</u> , 14:397-440;					
		Fries, J.F., et al. (1990) <u>J. Rheumatol.</u> , 17(22):12-15;					
		Genzyme Catalog, (1991) pp. 79-80;					
		Harris, et al. (1993) <u>Tibtech</u> , 11:42-44;					
		Herzog, C., et al. (1987) <u>Lancet</u> , 2(8573):1461-1462;					
		Hozzof, et al. (1987) <u>Lancet</u> , 11:1461-1462;					
		Kahan, B.D. (1992) <u>Curr. Opin. Immunol.</u> , 4:553-560;					
		Kalden, J.R., et al. (1995) <u>Curr. Opin. Rheum.</u> , 7(3):191-197;					
		Kalden, J.R., et al. (1997) <u>Curr. Opin. Rheum.</u> , 9:206-212;					
EXAMINER			DATE CONSIDERED				
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this from with next communication to applicant.</p>							

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 1481/65019-CA-Z-PCT- US/JPW/AJM/CY		Serial No. Not Yet Known	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				Applicants Marc Feldmann, et al.		Group Not Yet Known	
				Filing Date January 20, 2004			
U.S. PATENT DOCUMENTS							
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
FOREIGN PATENT DOCUMENTS							
		Document Number	Date	Country	Class	Subclass	Translation
							Yes No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	Kavanaugh, et al. (1996) <u>Arth. Rheum.</u> , 39(9):18-22 (Abstract 575);						
	Kozarek (1989) <u>Ann. Int. Med.</u> , 110:353-356;						
	Littman, B.H., et al. (1995) <u>Arthritis Rheum.</u> , 38:29-37;						
	Maini, R.N. (1996) <u>J. Royal College of Physicians of London</u> , 30(4):344-351;						
	Maini, R.N. (1995) <u>Arth. Rheum.</u> , Suppl. 38(9):S186 (Abstract 200);						
	Matsumiya, G., et al. (1996) <u>Transplant Proceed.</u> , 28(2):751-753;						
	Moreland, L.W., et al. (1995) <u>Arthritis Rheum.</u> , 38:1581-1588;						
	Moreland, L.W., et al. (1996) <u>J. Rheumatol.</u> , (Suppl. 44) 23:78-83;						
	Paul, W.E. (1993) <u>Fundamental Immunology</u> , 3 rd edition, Raven Press, NY, pp. 807-812;						
EXAMINER			DATE CONSIDERED				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this from with next communication to applicant.							

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 1481/65019-CA-Z-PCT-US/JPW/AJM/CY		Serial No. Not Yet Known	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				Applicants Marc Feldmann, et al.		Group Not Yet Known	
				Filing Date January 20, 2004			
U.S. PATENT DOCUMENTS							
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
FOREIGN PATENT DOCUMENTS							
		Document Number	Date	Country	Class	Subclass	Translation <div style="display: flex; justify-content: space-between; font-size: small;"> Yes No </div>
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	Paul, W.E. (1993) <u>Fundamental Immunology</u> , 3 rd edition, Raven Press, NY, p. 242;						
	Qin, S., et al. (1987) <u>Eur. J. Immunol.</u> , 17:1159-1165;						
	Richardson, C., et al. (1995) <u>Br. J. Clin. Prac.</u> , 49:135-139;						
	Sander, O., et al. (1995) <u>Arthritis Rheum.</u> , 38:S266 (Abstract 678);						
	Sosman, J.A., et al. (1993) <u>J. Pediatric Hematol. Oncol.</u> , 15(2):185-195;						
	Stein, C.M., et al. (1994) <u>Arthritis Rheum.</u> , 37:S252;						
	Strober, et al. (1990) <u>Immunol. Reviews</u> , 118:233-255;						
	Stuart, et al. (1986) <u>Laboratory Investigation</u> , 34:1-13;						
	Waldmann, T.A. (1991) <u>Science</u> , 252:1657-1662;						
	Weinblatt, M.E., et al. (1994) <u>Arthritis Rheum.</u> , 37:1492-1498; and						
	Williams, R.O., et al. (1995) <u>Immunology</u> , 84:433-439.						
EXAMINER			DATE CONSIDERED				
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this from with next communication to applicant.</small>							